All of the press
releases have been provided as Adobe Acrobat documents.
Click on the appropriate title to open the document.
To download a free Adobe Acrobat reader click the following
icon: **ACROBAT ICON  .
October 25, 2005
OncoGenex Initiates Fourth Phase 2 Clinical Trial of OGX-011 in Cancer
October 12, 2005
OncoGenex Initiates Third of Four Phase 2 Clinical Trials of OGX-011 in Cancer
September
20, 2005
OncoGenex Hires Senior Executives and Establishes U.S.
Based Clinical and Regulatory Operations
September
7, 2005
OncoGenex Phase I Study of OGX-011 in Prostate Cancer
Meets Primary and Secondary Endpoints
August
16, 2005
OncoGenex Announces Completion of $12.8 Million Venture
Financing
August
9, 2005
OncoGenex Initiates Second of Four Phase 2 Clinical
Trials of OGX-011 in Cancer
July
19, 2005
OncoGenex Initiates First of Four Phase 2 Clinical Trials
of OGX-011 in Cancer
May
11, 2005
OncoGenex to Present New Phase 1 Data on Lead Cancer
Drug Candidate OGX-011 at 2005 ASCO Annual Meeting
 2005
ASCO Poster
Phase I Trial Results:
Combination with docetaxel
April
26, 2005
OncoGenex Announces In-Licensing and Development Plans
for a Novel Cancer Therapeutic
March
16, 2005
Oncogenex Technologies and Isis Pharmaceuticals expand
Antisense drug development partnership in Oncology
|
